Communiqués Ribomic Inc.

Actions

4591

JP3974850004

Marché Fermé - Japan Exchange Autres places de cotation 08:00:00 03/07/2024			Varia. 5j.	Varia. 1 janv.
99 ^JPY	-8,33 %		+5,32 %	-8,33 %

13/02	Ribomic Inc. annonce ses résultats pour les neuf mois se terminant le 31 décembre 2023	CI
17/01	Ribomic s'engage dans une collaboration de recherche de médicaments avec Ajinomoto	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

RIBOMIC Phase I and II Data Published in the Eye: Full TOFU/RAMEN/TEMPURA Trial Results Demonstrate Clinical Proof of Concept of Umedaptanib Pegol in Exudative Age-Related Macular Degeneration (nAMD)	05/12	BU
RIBOMIC : Announces Issuance of US Patent for its RBM-010, Novel Drug Candidate for Osteoarthritis	29/07/22	PU
Ribomic : 【Delayed】RIBOMIC Announces Publication Highlighting Novel Approach to Generate Aptamer using AI in the Nature Computational Science	10/06/22	PU
RIBOMIC : Announces Completion of IND submission for an Observational Study for Continuous Phase 2 Trial of RBM-007 for Treatment of Achondroplasia	19/04/22	PU
RIBOMIC : Provides Update on RBM-007 Program in Wet Age-Related Macular Degeneration	23/03/22	PU
RIBOMIC : Announces Presentation Materials of the 40th Annual J.P. Morgan Healthcare Conference	11/01/22	PU
RIBOMIC : Announces Preliminary Topline Data from Phase 2 Trials of RBM-007 for Wet Age-Related Macular Degeneration	28/12/21	PU
RIBOMIC : Announces Presentation at the 40th Annual J.P. Morgan Healthcare Conference	23/12/21	PU
RIBOMIC Announces RBM-007 Phase 1 Clinical Trial Results for Achondroplasia	15/11/21	BU
RIBOMIC : Announces RBM-007 Phase 1 Clinical Trial Results for Achondroplasia	15/11/21	PU
Summary of Non-Consolidated Financial Results for the Six Months Ended September 30 2021(Based on Japanese GAAP)	09/11/21	PU
RIBOMIC : Announces Presentation of Masked Preliminary Interim Data from Phase 2 Trials of RBM-007 for Wet Age-Related Macular Degeneration at the Retina Society 2021 Meeting	30/09/21	BU
RIBOMIC : Announces Presentation of Masked Preliminary Interim Data from Phase 2 Trials of RBM-007 for Wet AMD at the Retina Society 2021 Meeting	30/09/21	PU
RIBOMIC : Completes Patient Enrollment of its US Phase 2 Open-Label Extension Clinical Trial of RBM-007 for wet AMD (RAMEN Study)	30/08/21	PU
RIBOMIC : Completes Patient Enrollment of its US Phase 2 Clinical Trial of RBM-007 for Wet Age-Related Macular Degeneration (TOFU Study)	05/08/21	PU
RIBOMIC : Announces First Patient Dosed in an Investigator Sponsored Trial of RBM-007 in treatment naive wet AMD Patients	12/07/21	PU
RIBOMIC : Announces Termination of MTA with The Pritzker Neuropsychiatric Disorders Research Consortium	28/05/21	PU
Ribomic : Summary of Non-Consolidated Financial Results for the Year Ended March 31, 2021 (Based on Japanese GAAP)	25/05/21	PU
RIBOMIC : Announces Completion of its Phase I Trial of RBM-007 for the Treatment of Achondroplasia	21/05/21	PU
RIBOMIC : Announces Publication of a Research Paper on an Aptamer Creation Platform Technology for Membrane Receptor GPCR	21/05/21	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Ribomic Inc.

Actions

4591

JP3974850004

Communiqués

Filtres